Prevalence, severity and clinical outcome of malnutrition in gastroenteropancreatic neuroendocrine tumors Abstract #136

Introduction: Malnutrition is well-known to unfavorably influence clinical prognosis in patients (pts) with malignant diseases. However, in patients with neuroendocrine tumors (NET) prevalence and outcome of malnutrition are unknown although the gastroenteropancreatic system is most frequently involved.
Aim(s): In this study, we assessed the nutritional status in NET patients and aimed to determine the correlation between nutritional status and specifc characteristics of NET disease, treatment and clinical outcome parameters.
Materials and methods: A cross-sectional study was performed evaluating the nutritional status of patients with histologically proven NET. Malnutrition screening scores (SGA, NRS), anthropometric measurements, surrogate parameters and bioelectrical impedance analysis (BIA) measurements were used for nutritional status assessment. Nutritional status was correlated with tumor characteristics and parameters of both short- and long-term outcome, particularly overall tumor survival.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr Sebastian Maasberg

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2098 Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status
Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Sophie Pevny
#2684 Tumour-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumour Patients after Curative Resection
Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) are steadily increasing in prevalence and present several clinical challenges.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Wuhu Zhang
Authors: Zhang W, Wang W, ...
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#2773 Impact on Outcome in Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) Included in Prospective Clinical Trials (CT)
Introduction: Access to CT offers cancer pts the opportunity to receive new treatments and better monitoring of efficacy and toxicity. The increase of systemic therapy options in advanced NENs has relegated the inclusion of pts in CT to later lines of treatment as suggested in most guidelines.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Jorge Hernando-Cubero
#2841 Novelties in Primary and Metastatic GEP-NENs Clinical Outcome Investigation
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) WHO classification, using strict cut-offs, should reflect their biological features. In real world, strict cut-offs not adequately segregate prognostic groups, in particular on metastasis (M).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Massimo Milione